Invex Therapeutics Ltd. (AU:IXC) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Invex Therapeutics Ltd has announced the results of its Annual General Meeting, where several resolutions, including the adoption of the remuneration report and the election of directors, were carried, while the issuance of securities under an incentive plan was not approved. The company continues its focus on repurposing the drug Exenatide for neurological treatments, underlining its commitment to innovation in biopharmaceuticals.
For further insights into AU:IXC stock, check out TipRanks’ Stock Analysis page.